FormWeb • eculizumab

Eculizumab is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.

See HERE for more information and workflow.

See HERE for additional pharmacy workflow details.

Epysqli® is the preferred product at Legacy, when eculizumab is approved, effective September 23^rd, 2025

Eculizumab requires patient and provider REMS enrollment prior to dispensing

Patients should be up to date with meningococcal vaccinations prior to treatment initiation.

- Patients should receive their meningococcal vaccinations at least 2 weeks prior to treatment initiation.

- If meningococcal vaccinations not up to date, prophylactic antibiotics should be initiated and administer meningococcal vaccines as soon as possible.

Epysqli® (eculizumab-aagh) Risk Evaluation and Mitigation Strategy (REMS) webpage
- Website outlines REMS requirements and documentation needed for dispensing

Epysqli® (eculizumab-aagh) REMS Healthcare Provider Safety Brochure

Combined Ultomiris® (ravulizumab) and Soliris® (eculizumab) Risk Evaluation and Mitigation Strategy (REMS) webpage
- Website outlines REMS requirements and documentation needed for dispensing

Combined Ultomiris® and Soliris® REMS Healthcare Provider Safety Brochure

Last updated: Sep. 22, 2025

Black Box Warning: Meningococcal Infection
REMS: Soliris Injection
Restricted Restricted Medication

This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.